Bruno Domon, Ph.D., is an expert in biological mass spectrometry and proteomics, heading the Luxembourg Clinical Proteomics Center, at L.I.H., where he leads a program funded by the Fonds National de la Recherche (PEARL grant).  His main focus is the development of novel mass spectrometry-based proteomics methodologies, and their application to biomarker discovery and evaluation.  His current interest is in personalized medicine and personalized therapies and he is collaborating with the clinicians to develop new diagnostics tools in oncology.

Previously, he was group leader and principal investigator at the Institute of Molecular Systems Biology at ETH in Zurich (2005-2009).  As director at Celera Genomics in Rockville MD (2001-2004) he led the proteomics program, focused on the identification of cell surface proteins for oncology therapeutic development and diagnostics. 

Development and Implementation of Parallel Reaction Monitoring Assays

Quantitative proteomics is gradually shifting from conventional SRM to high-resolution parallel reaction monitoring (PRM) assays, typically performed on a quadrupole-orbitrap instrument.  The technique is characterized by a high selectivity, which increases the analytical performances and the reproducibility of analyses.  It has introduced a change in the paradigm of targeted experiments, by decoupling acquisition and data processing.  This has prompted a new analytical workflow in which these two actions are driven by two distinct methods. A complete informatics solution accounting for these specificities was developed to fully automate the design, execution, and data processing of PRM experiments.  A reference spectral library (containing meta-information) constitutes the basis to design both the data acquisition and data processing methods.